Luoxin Pharmaceuticals Group Stock Co Ltd (002793) — Working Capital to Net Assets Ratio
Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has a Working Capital to Net Assets ratio of -40.6% as of June 2026. Working capital of CN¥-488.68 Million (current assets of CN¥1.85 Billion minus current liabilities of CN¥2.34 Billion) is measured against net assets of CN¥1.20 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how many days can Luoxin Pharmaceuticals Group Stock Co Lt fund operations to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Luoxin Pharmaceuticals Group Stock Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Luoxin Pharmaceuticals Group Stock Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at -40.6%, reflecting working capital of CN¥-488.68 Million against net assets of CN¥1.20 Billion CNY. For the complete balance sheet picture, see how large is Luoxin Pharmaceuticals Group Stock Co Lt's balance sheet.
Annual Working Capital to Net Assets for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check 002793 financial resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -29.9% | CN¥-369.11 Million | CN¥1.24 Billion | CN¥1.93 Billion | CN¥2.30 Billion | ▲ +21.8 pp |
| 2024 | -51.6% | CN¥-753.60 Million | CN¥1.46 Billion | CN¥1.78 Billion | CN¥2.54 Billion | ▼ -57.5 pp |
| 2023 | 5.8% | CN¥149.96 Million | CN¥2.57 Billion | CN¥2.07 Billion | CN¥1.92 Billion | ▼ -4.7 pp |
| 2022 | 10.5% | CN¥347.07 Million | CN¥3.31 Billion | CN¥4.72 Billion | CN¥4.37 Billion | ▼ -39.4 pp |
| 2021 | 49.9% | CN¥2.36 Billion | CN¥4.74 Billion | CN¥6.37 Billion | CN¥4.01 Billion | ▲ +5.9 pp |
| 2020 | 44.0% | CN¥1.91 Billion | CN¥4.35 Billion | CN¥4.88 Billion | CN¥2.97 Billion | ▼ -4.6 pp |
| 2019 | 48.5% | CN¥1.92 Billion | CN¥3.96 Billion | CN¥4.87 Billion | CN¥2.95 Billion | ▼ -14.1 pp |
| 2018 | 62.6% | CN¥570.01 Million | CN¥909.89 Million | CN¥817.23 Million | CN¥247.22 Million | ▲ +17.9 pp |
| 2017 | 44.7% | CN¥337.36 Million | CN¥754.19 Million | CN¥477.18 Million | CN¥139.82 Million | ▼ -14.6 pp |
| 2016 | 59.4% | CN¥414.53 Million | CN¥698.33 Million | CN¥526.40 Million | CN¥111.87 Million | ▲ +28.2 pp |
| 2015 | 31.1% | CN¥105.66 Million | CN¥339.50 Million | CN¥315.76 Million | CN¥210.10 Million | ▼ -10.9 pp |
| 2014 | 42.1% | CN¥132.65 Million | CN¥315.46 Million | CN¥247.01 Million | CN¥114.36 Million | ▲ +2.4 pp |
| 2013 | 39.7% | CN¥99.80 Million | CN¥251.50 Million | CN¥211.60 Million | CN¥111.80 Million | ▲ +8.0 pp |
| 2012 | 31.7% | CN¥65.17 Million | CN¥205.54 Million | CN¥231.62 Million | CN¥166.44 Million | ▼ -23.8 pp |
| 2011 | 55.5% | CN¥84.35 Million | CN¥151.87 Million | CN¥204.43 Million | CN¥120.07 Million | — |